MediWound

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

MediWound reports $5M revenue, advances trials and manufacturing capacity

MediWound's Q1 2024 performance reflects solid revenue from NexoBrid, progress on manufacturing, and strategic advancements in clinical trials and FDA interactions.
While facing challenges in profitability and operational expenses, the company's strengths in innovation, market acceptance, and growth opportunities position it for future success.
With a focus on operational excellence and expansion plans, MediWound remains well-positioned to capitalize on market opportunities and drive sustainable growth.

MediWound reports revenue growth but faces profit challenges in Q2 2024

MediWound's Q2 2024 performance showed revenue growth but faced challenges with decreased gross profit and increased losses. Despite liquidity concerns, the company is capitalizing on opportunities in NexoBrid and EscharEx developments. Analyst interest in capacity expansion and trial funding indicates market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

YAVNE, Israel, Feb. 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchase agreement for the sale and purchase of1,964,286 shares of the Company's ordinary shares, par value NIS 0.07, at a purchase price of $14 per share, in a registered direct offering. The Company expects to close the offering on or about February 7, 2023, subject to the satisfaction of customary closing conditions.

MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Japan is the first country in the world to approve NexoBrid for people of all ages;  pediatric and adult populations

MediWound Expands NexoBrid's Global Presence with Marketing Approval in Japan

NexoBrid gain ed marketing approval in Switzerland ; l aunch expected first quarter 2023

MediWound Strengthens European Presence of NexoBrid®

MW005 s hown to b e s afe and w ell-tolerated

MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company

MediWound Expands Global Presence as NexoBrid® Gains Approval in India

YAVNE, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound” or the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it intends to effect a 1-for-7 reverse share split of its ordinary shares. Subject to the Company's satisfaction of Nasdaq Operations notice requirements, the scheduled effective date is December 20, 2022, with trading on a reverse split-adjusted basis to begin at market open on that day. Trading of the Company's ordinary shares will continue on the Nasdaq Global Market under the symbol “MDWD,” but the shares will trade under the new CUSIP number, M68830112. In the event of a delay in the effective date, the Company will update the public via a subsequent press release.

MediWound Announces a 1-for-7 Reverse Share Split

MediWound Ltd. (NASDAQ:MDWD ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Monique Kosse - MD, LifeSci Advisors Ofer Gonen - CEO Boaz Gur-Lavie - CFO Conference Call Participants Josh Jennings - Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - H.C.

MediWound Ltd. (MDWD) Q3 2022 Earnings Call Transcript

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

$30.5 million in gross proceeds raised; operating cash runway through 2025

MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update

Paper published in the November 2022 issue of Podiatry Management (Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM, MS)

MediWound's EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs

Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time

MediWound to Report Third Quarter 2022 Financial Results

Esteemed group of industry leaders to contribute expertise and experience to MediWound's strategic and operational activities Esteemed group of industry leaders to contribute expertise and experience to MediWound's strategic and operational activities

MediWound Announces Formation of Strategic Advisory Board

EscharEx's promising results from the completed Phase 2 trials were highlighted EscharEx's promising results from the completed Phase 2 trials were highlighted

MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

Gross Proceeds of $30.5 Million Raised Gross Proceeds of $30.5 Million Raised

MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings

YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchase agreement with several institutional and accredited investors (the “Registered Direct Securities Purchase Agreement”) for the sale and purchase of 7,575,513 shares of the Company's ordinary shares, par value NIS 0.01 (the “Ordinary Shares”), at a purchase price of $1.75 per share, in a registered direct offering (the “Registered Direct Offering”). Additionally pursuant to the Registered Direct Securities Purchase Agreement, the Company has also agreed to issue to these investors unregistered warrants (the “Warrants”) to purchase up to 7,575,513 Ordinary Shares in a concurrent private placement. The Warrants will have an exercise price of $1.925 per Ordinary Share and will become exercisable upon the Company's receipt of shareholder approval to increase the number of its authorized Ordinary Shares, pursuant to the Company's Amended and Restated Articles of Association, and will expire four years thereafter. The gross proceeds of the Registered Direct Offering are expected to be approximately $13.26 million. The Company expects the Registered Direct Offering to close on or about September 26, 2022, subject to the satisfaction of customary closing conditions.

MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million

Upon approval, NexoBrid will serve as a safe and effective non-surgical treatment option in the EU for children with severe burns Upon approval, NexoBrid will serve as a safe and effective non-surgical treatment option in the EU for children with severe burns

EMA Accepts MediWound's Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns

YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced its successful and meaningful presence at the recently concluded 19th European Burns Association (EBA) Congress held in Turin, Italy on September 7-10, 2022.

MediWound's NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress

MediWound Ltd. (NASDAQ:MDWD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Bergin - Cowen Ryan Zimmerman - BTIG Arthur He - H.C.

MediWound Ltd. (MDWD) CEO Ofer Gonen on Q2 2022 Results - Earnings Call Transcript

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 11.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q2 Loss, Misses Revenue Estimates

Positive Results in Two Phase 2 Trial s of EscharEx

MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates

Mr. N achum Shamir appointed as Chairman of the Board

MediWound Enhances Its Board and Executive Leadership Team

Prescription Drug User Fee Act (PDUFA) target date of January 1, 2023 Prescription Drug User Fee Act (PDUFA) target date of January 1, 2023

MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET

MediWound Schedules Second Quarter 2022 Financial Results

MW005 Shown to Be Safe and Well-Tolerated Target Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept

News for MediWound Stock (MDWD)